Institution
Hospital Universitario La Paz
Healthcare•Madrid, Spain•
About: Hospital Universitario La Paz is a healthcare organization based out in Madrid, Spain. It is known for research contribution in the topics: Population & Medicine. The organization has 8960 authors who have published 11499 publications receiving 191509 citations.
Topics: Population, Medicine, Cancer, Transplantation, Haemophilia
Papers published on a yearly basis
Papers
More filters
••
Royal Brisbane and Women's Hospital1, University of Maryland, Baltimore2, Paris Diderot University3, Hospital Universitario La Paz4, Saint Joseph's University5, Mount Sinai Hospital, Toronto6, Pfizer7, University of Florence8, Medisch Spectrum Twente9, Leiden University Medical Center10, Paris Descartes University11
TL;DR: The goal was to develop multinational estimates for minimal clinically important improvement (MCII) and patient acceptable symptomatic state (PASS) for patients with symptomatic Ehlers-Danlos syndrome.
Abstract: The ability to interpret scores from patient-reported outcome measures at the individual patient level depends on the availability of valid, clinically meaningful benchmarks of response and state attainment. The goal was to develop multinational estimates for minimal clinically important improvement (MCII) and patient acceptable symptomatic state (PASS). A multinational sample of patients with osteoarthritis (OA) was evaluated before and 4 weeks after treatment with nonsteroidal antiinflammatory drugs. Patients completed either the Western Ontario and McMaster Osteoarthritis Index (WOMAC) numerical rating scale 3.1 (hip and knee OA) or the Australian/Canadian Index (AUSCAN) numerical rating scale 3.1 (hand OA) before and after treatment. Patients rated the clinical importance of their response to treatment and their satisfaction with the health state achieved, from which multinational MCII and PASS estimates were calculated for both the WOMAC and AUSCAN indices. A total of 609 patients from 7 countries participated in the study. MCII and PASS estimates varied slightly by instrument and subscale. Absolute (percentage) change for MCII ranged 6-9 (10% to 17%) for WOMAC and 4-9 (8% to 15%) for AUSCAN. PASS estimates ranged 39-48 for WOMAC and 38-45 for AUSCAN. Some between-country variation was observed in MCII and PASS. Preliminary multinational estimates for MCII and PASS have been developed for several countries. Further research is required to evaluate the robustness, temporal consistency, and age- and sex-dependency of the preliminary estimates as well as their generalizability to other countries, languages, cultures, regions, and other condition-specific outcome measures.
79 citations
••
University of Zurich1, University of Paris2, Queen Alexandra Hospital3, Harvard University4, University of Erlangen-Nuremberg5, University of Würzburg6, Hospital Universitario La Paz7, Versailles Saint-Quentin-en-Yvelines University8, University of Barcelona9, University of Bern10, Radboud University Nijmegen Medical Centre11, University of North Carolina at Chapel Hill12
TL;DR: The updated European Association of Urology (EAU) guidelines for metastatic urothelial carcinoma are presented in this paper, which provides detailed and contemporary information on the treatment of metastatic UROL cancer for incorporation into clinical practice.
79 citations
••
TL;DR: Cell-based therapy has demonstrated safety and efficacy in experimental animal models of stroke, as well as safety in stroke patients, but various questions remain regarding the therapeutic window, dosage, route of administration, and the most appropriate cell type and source.
Abstract: Cell-based therapy has demonstrated safety and efficacy in experimental animal models of stroke, as well as safety in stroke patients. However, various questions remain regarding the therapeutic window, dosage, route of administration, and the most appropriate cell type and source, as well as mechanisms of action and immune-modulation to optimize treatment based on stem cell therapy. Various delivery routes have been used in experimental stroke models, including intracerebral, intraventricular, subarachnoid, intra-arterial, intraperitoneal, intravenous, and intranasal routes. From a clinical point of view, it is necessary to demonstrate which is the most feasible, safest, and most effective for use with stroke patients. Therefore, further experimental studies concerning the safety, efficacy, and mechanisms of action involved in these therapeutic effects are required to determine their optimal clinical use.
78 citations
••
TL;DR: Ultrasonography with power Doppler shows that the ultrasound appearances of subclinical enthesitis in psoriasis differ from the subclinicalEnthesopathy in PsA, with PsA patients having more PD, suggestive of a more inflammatory or vascular process in psA.
Abstract: Objective Subclinical enthesopathy is recognised in both psoriasis and psoriatic arthritis (PsA). This study used ultrasonography with power Doppler (PD) to test the hypothesis that subclinical enthesopathy in PsA was associated with an ‘inflammatory’ or vascular phenotype compared to that seen in psoriasis. Methods 100 patients with a mean age of 46.3 years (SD 15) (42 with psoriasis and 58 with PsA) and 23 matched healthy controls (HC) from two centres were included. 1230 lower limb entheses were scanned by ultrasonographers blinded to clinical details. Both inflammatory and chronic features of enthesopathy were scored. Results Psoriasis patients (with or without arthritis) were more likely to express a vascular phenotype, with higher inflammation-related enthesopathy scores than HC (for inflammation p Conclusions This study shows that the ultrasound appearances of subclinical enthesitis in psoriasis differ from the subclinical enthesitis in PsA, with PsA patients having more PD. This is suggestive of a more inflammatory or vascular process in PsA, and offers potentially novel insights into the progression from skin to joint disease in psoriasis.
78 citations
••
St. Joseph's Hospital and Medical Center1, European Union2, Saitama Medical University3, Samsung Medical Center4, Hebron University5, University of Lyon6, Université de Montréal7, Cedars-Sinai Medical Center8, Institut Gustave Roussy9, University of Texas MD Anderson Cancer Center10, Innsbruck Medical University11, Hospital Universitario La Paz12, National and Kapodistrian University of Athens13, Amgen14, University of Toronto15
TL;DR: Overall survival (OS) in the intent-to-treat population and clinically relevant subgroups and time to second disease progression (PFS-2) confirmed that the PFS benefit associated with trebananib was maintained through the second Disease progression independent of the choice of subsequent therapy.
78 citations
Authors
Showing all 9020 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jaakko Tuomilehto | 115 | 1285 | 210682 |
Vincent Soriano | 87 | 762 | 34084 |
Lina Badimon | 86 | 682 | 35774 |
Francisco J. Blanco | 84 | 789 | 33319 |
Michael A. Gatzoulis | 82 | 478 | 32562 |
Jose Lopez-Sendon | 81 | 460 | 41809 |
Victor Moreno | 80 | 635 | 31511 |
Joaquín Dopazo | 75 | 396 | 24790 |
Fernando Rodríguez-Artalejo | 74 | 512 | 23296 |
José R. Banegas | 74 | 421 | 28249 |
Michael Becker | 72 | 317 | 18189 |
Gianfranco Ferraccioli | 70 | 402 | 26515 |
Maria-Victoria Mateos | 66 | 480 | 24278 |
Manuel Romero-Gómez | 64 | 420 | 19006 |
Eulogio García | 63 | 270 | 15354 |